Literature DB >> 6150182

Association between cyclosporin neurotoxicity and hypomagnesaemia.

C B Thompson, C H June, K M Sullivan, E D Thomas.   

Abstract

The serum magnesium levels of all 12 allogeneic bone-marrow transplant recipients who experienced the neurotoxic effects of cyclosporin (CyA) were more than two standard deviations below the normal range. The neurological events seemed to segregate into three separate syndromes. 7 patients had grand-mal seizures, which occurred within the first several weeks of CyA therapy (median onset 12 days). At the time of their first seizure all 7 patients had hypomagnesaemia, which had developed rapidly over the preceding 1-3 weeks. 3 patients had four episodes of cerebellar ataxia, tremor, and depression. These subacute episodes developed after prolonged CyA therapy (median onset 67 days). Each episode was associated with hypomagnesaemia. 2 patients had a transient episode of expressive aphasia following a long period of hypomagnesaemia. In all cases symptoms resolved or did not recur with adequate magnesium replacement. These data suggest that CyA neurotoxicity is associated with hypomagnesaemia and may be treated or prevented with magnesium replacement.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6150182     DOI: 10.1016/s0140-6736(84)91556-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  43 in total

Review 1.  Neuropsychiatric complications of liver transplantation.

Authors:  A Stracciari; M Guarino
Journal:  Metab Brain Dis       Date:  2001-06       Impact factor: 3.584

2.  Seizure treatment in transplant patients.

Authors:  Paul W Shepard; Erik K St Louis
Journal:  Curr Treat Options Neurol       Date:  2012-08       Impact factor: 3.598

Review 3.  Drug-induced cerebellar ataxia: a systematic review.

Authors:  J van Gaalen; F G Kerstens; R P P W M Maas; L Härmark; B P C van de Warrenburg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

4.  Potential benefit of 1-alpha-cholecalciferol in hypomagnesaemia by cyclosporin.

Authors:  C J Pearce; J M Davies
Journal:  J Clin Pathol       Date:  1990-09       Impact factor: 3.411

5.  Variable incidence of cyclosporine and FK-506 neurotoxicity in hematopoeitic malignancies and marrow conditions after allogeneic bone marrow transplantation.

Authors:  Walter S Bartynski; Zella R Zeigler; Richard K Shadduck; John Lister
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

6.  Posterior reversible encephalopathy syndrome: a possible late interaction between cytotoxic agents and general anaesthesia.

Authors:  P S Rangi; W J Partridge; E S Newlands; A D Waldman
Journal:  Neuroradiology       Date:  2005-07-05       Impact factor: 2.804

Review 7.  Drug-induced hypomagnesaemia : scope and management.

Authors:  Jacob Atsmon; Eran Dolev
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

8.  Neurologic complications of FK 506.

Authors:  B H Eidelman; K Abu-Elmagd; J Wilson; J J Fung; M Alessiani; A Jain; S Takaya; S N Todo; A Tzakis; D Van Thiel
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

9.  Expressive dysphasia possibly related to FK506 in two liver transplant recipients.

Authors:  J Reyes; T Gayowski; J Fung; S Todo; M Alessiani; T E Starzl
Journal:  Transplantation       Date:  1990-12       Impact factor: 4.939

10.  Cyclosporin A toxicity: MRI appearance of the brain.

Authors:  M T Pace; T L Slovis; J K Kelly; S D Abella
Journal:  Pediatr Radiol       Date:  1995
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.